Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2021 Sep 4;8(10):2013–2024. doi: 10.1002/acn3.51449

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2021 The Authors. Annals of Clinical and Translational Neurology published by Wiley Periodicals LLC on behalf of American Neurological Association.

This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.

PMC Copyright notice

(A, C) cNfL (shades of blue) and sNfL (shades of red) concentrations in pg/mL over time before and during treatment with nusinersen for individual participants (n = 18). The two subgroups of SMA patients with 2 SMN2 and >2 SMN2 copies are displayed in different color intensities. The x‐axis shows treatment doses (black) and time from the initiation of nusinersen treatment (baseline, grey) in months. (B) Median cNfL levels and (D) median sNfL values represented by bars with dots showing individual values in comparison to the median sNfL values of healthy age‐matched controls (CTL).